A Phase I/III, First in Human Trial of the Bruton's Tyrosine Kinase Inhibitor M7583 in Patients with B-Cell Malignancies

被引：2
|
作者：
Jurczak, Wojciech [1 ]
Rule, Simon [2 ]
Townsend, William [3 ]
Tucker, David [4 ]
Sarholz, Barbara [5 ]
Scheele, Jurgen [6 ]
Gribben, John G. [7 ]
Zinzani, Pier Luigi [8 ]
机构：
[1] Jagiellonian Univ, Dept Haematol, Krakow, Poland
[2] Plymouth Univ, Dept Haematol, Sch Med, Plymouth, Devon, England
[3] Univ Coll London Hosp NHS Fdn Trust, NIHR UCLH Clin Res Facil, London, England
[4] Torbay Hosp, Dept Haematol, Torquay, England
[5] Merck KGaA, R&D Global Biostat & Epidemiol, Darmstadt, Germany
[6] Merck KGaA, Global Clin Dev, Darmstadt, Germany
[7] Queen Mary Univ London, Ctr Haematooncol, Barts Canc Inst, London, England
[8] Ist Ematol, Bologna, Italy
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-112808
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4161
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies
    Jurczak, Wojciech
    Rule, Simon
    Townsend, William
    Tucker, David
    Sarholz, Barbara
    Scheele, Juergen
    Dyroff, Martin
    Gribben, John G.
    Dlugosz-Danecka, Monika
    Zinzani, Pier Luigi
    LEUKEMIA & LYMPHOMA, 2021, 62 (10) : 2392 - 2399
  • [2] Phase I/II, first in human trial with M7583, a Bruton's tyrosine kinase inhibitor (BTKi), in patients with B cell malignancies
    Jurczak, W.
    Rule, S.
    Townsend, W.
    Tucker, D.
    Sarholz, B.
    Scheele, J.
    Gribben, J.
    Zinzani, P. L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [3] Phase I/II, first in human trial of the Bruton's tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies.
    Rule, Simon
    Tucker, David
    Kalapur, Anup
    Sarholz, Barbara
    Scheele, Jurgen
    Zinzani, Pier Luigi
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] First in Human, Phase I/II Trial of the Bruton's Tyrosine Kinase Inhibitor (BTKi) M7583 in Patients with B Cell Malignancies: Study Design and Initial Outcomes
    Jurczak, Wojciech
    Rule, Simon
    Townsend, William
    Tucker, David
    Dyroff, Martin
    Sarholz, Barbara
    Scheele, Jurgen
    Gribben, John G.
    Zinzani, Pier Luigi
    BLOOD, 2017, 130
  • [5] M7583 Is a Highly Selective and Potent Second Generation BTK Inhibitor for Treatment of B-Cell Malignancies
    Goodstal, Samantha M.
    Ma, Jianguo
    Lin, Jing
    Crandall, Timothy
    Crowley, Lindsey
    Bender, Andrew
    Iadevaia, Riham
    Clark, Anderson
    BLOOD, 2017, 130
  • [6] Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial
    Shah, Nirav N.
    Wang, Michael
    Roeker, Lindsey E.
    Patel, Krish
    Woyach, Jennifer A.
    Wierda, William G.
    Ujjani, Chaitra S.
    Eyre, Toby A.
    Zinzani, Pier Luigi
    Alencar, Alvaro J.
    Ghia, Paolo
    Lamanna, Nicole
    Hoffmann, Marc S.
    Patel, Manish R.
    Flinn, Ian
    Gerson, James N.
    Ma, Shuo
    Coombs, Catherine C.
    Cheah, Chan Y.
    Lech-Maranda, Ewa
    Fakhri, Bita
    Kim, Won Seog
    Barve, Minal A.
    Cohen, Jonathon B.
    Jurczak, Wojciech
    Munir, Talha
    Thompson, Meghan C.
    Tsai, Donald E.
    Bao, Katherine
    Cangemi, Nicholas A.
    Kherani, Jennifer F.
    Walgren, Richard A.
    Han, Hongmei
    Ruppert, Amy S.
    Brown, Jennifer R.
    HAEMATOLOGICA, 2025, 110 (01) : 92 - 102
  • [7] Acalabrutinib: A Selective Bruton Tyrosine Kinase Inhibitor for the Treatment of B-Cell Malignancies
    Abbas, Hussein A.
    Wierda, William G.
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [8] Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
    Aw, Andrew
    Brown, Jennifer R.
    DRUGS & AGING, 2017, 34 (07) : 509 - 527
  • [9] Bruton Tyrosine Kinase Degraders in B-Cell Malignancies
    Huynh, Tiana
    Rodriguez-Rodriguez, Sonia
    Danilov, Alexey V.
    MOLECULAR CANCER THERAPEUTICS, 2024, 23 (05) : 619 - 626
  • [10] Current Status of Bruton’s Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies
    Andrew Aw
    Jennifer R. Brown
    Drugs & Aging, 2017, 34 : 509 - 527
12345